diff --git a/index.xml b/index.xml
index 258e9b66..921c0933 100644
--- a/index.xml
+++ b/index.xml
@@ -37,7 +37,7 @@ While we expect the updated toolkit to be released very soon, we wanted to provi
 coronaviridae Coronavirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.
 flaviviridae Flavivirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.</description></item><item><title>Software</title><link>https://asapdiscovery.org/outputs/software/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/software/</guid><description>Software produced by ASAP.
 argos [GitHub] A web-based visualization tool for viewing DMS data on protein structures that allows users to generate and share these views using a web UI. See &amp;lsquo;choppa&amp;rsquo; package below. Contributing Projects and Cores: Project 2 Computational Chemistry Core asapdiscovery [GitHub] [Documentation] Monorepository for running computational chemistry project support for ASAP&amp;rsquo;s viral targets, including docking, free energy calculations, chemoinformatics and machine learning. Contributing Projects and Cores: Project 5 Computational Chemistry Core choppa [GitHub] [Documentation] A Python library for visualizing Deep Mutational Scanning data and other fitness data directly onto protein structures to enable fitness-informed decision-making in medicinal chemistry workflows in P2-P5 of ASAP&amp;rsquo;s drug discovery pipeline.</description></item><item><title>Targeting Opportunities</title><link>https://asapdiscovery.org/outputs/targeting-opportunities/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/targeting-opportunities/</guid><description>A targeting opportunity provides an overview of the opportunity for targeting new antivirals to a specific target protein and mode of action. This overview is intended to summarize relevant information for drug hunters, including the relevant domain and binding sites to target, notable chemical matter, rationale for antiviral effects, and other useful information in prosecuting a discovery compaign aginst the target.
-Targeting Opportunity: SARS-CoV-2 / MERS-CoV Mpro protease [Targeting Opportunity] Contributing Projects and Cores: Project 1 Project 5 [2023-03-19] Initial draft [2024-04-29] Major update of the targeting opportunity covering clinical background, history of outbreaks, viral biology, target biochemistry, phylogenetic analysis, etc.</description></item><item><title>Molecules</title><link>https://asapdiscovery.org/outputs/molecules/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/molecules/</guid><description>SARS-CoV-2/MERS-CoV Mpro lead optimization assay data [metadata] [(negative) biochemical and liver microsome assay data [Oct 2023]] [(negative) biochemical and liver microsome assay data [Mar 2024]] [SARS-CoV-2 Mpro assay protocol] [MERS-CoV Mpro assay protocol] This data release contains assay data for compounds ASAP is not pursuing toward nomination of a development candidate as part of this discovery program. Contributing Projects and Cores: Project 5 Biochemical Assay Core Data Core [2023-04-30] Initial public release of negative biochemical activity data for 182 molecules.</description></item><item><title>Structures</title><link>https://asapdiscovery.org/outputs/structures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/structures/</guid><description>MERS-CoV/SARS-CoV-2 Mpro protease ASAP-COV-MPRO XChem crystallographic fragment screen of SARS-CoV-2 Mpro xray-fragment-screen [ 2020-03-18 ] Contributing Projects and Cores: Project 2 Structural Biology Core We performed an exhaustive crystallographic fragment screen to probe the Mpro active site, and to identify opportunities for fragment merging or growing. Additionally, a library of mild electrophilic fragments was screened by mass spectrometry for probing the binding properties around the active site cysteine. Overall, a total of 1742 soaking and 1139 co-crystallization experiments resulted in 1877 mounted crystals.</description></item><item><title>Publications</title><link>https://asapdiscovery.org/outputs/publications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/publications/</guid><description>ASAP aims to publish preprints to ensure our scientific advances are rapidly and openly available.</description></item><item><title>Analysis of Circulating Variants</title><link>https://asapdiscovery.org/outputs/circulating-variants/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/circulating-variants/</guid><description>Analysis of circulating variants of SARS-CoV-2 nsp5 Mpro protease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted. Analysis of circulating variants of SARS-CoV-2 nsp15 endoribonuclease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted.</description></item><item><title>Target Product Profiles (TPPs)</title><link>https://asapdiscovery.org/outputs/target-product-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-product-profiles/</guid><description>A Target Product Profile (TPP) describes the desired characteristics of a drug product aimed to treat a particular disease or set of diseases.
+Targeting Opportunity: SARS-CoV-2 / MERS-CoV Mpro protease [Targeting Opportunity] Contributing Projects and Cores: Project 1 Project 5 [2023-03-19] Initial draft [2024-04-29] Major update of the targeting opportunity covering clinical background, history of outbreaks, viral biology, target biochemistry, phylogenetic analysis, etc.</description></item><item><title>Molecules</title><link>https://asapdiscovery.org/outputs/molecules/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/molecules/</guid><description>SARS-CoV-2/MERS-CoV Mpro lead optimization assay data [metadata] [(negative) biochemical and liver microsome assay data [Oct 2023]] [(negative) biochemical and liver microsome assay data [Mar 2024]] [SARS-CoV-2 Mpro assay protocol] [MERS-CoV Mpro assay protocol] This data release contains assay data for compounds ASAP is not pursuing toward nomination of a development candidate as part of this discovery program. Contributing Projects and Cores: Project 5 Biochemical Assay Core Data Core [2023-04-30] Initial public release of negative biochemical activity data for 182 molecules.</description></item><item><title>Structures</title><link>https://asapdiscovery.org/outputs/structures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/structures/</guid><description>MERS-CoV/SARS-CoV-2 Mpro protease ASAP-COV-MPRO XChem crystallographic fragment screen of SARS-CoV-2 Mpro xray-fragment-screen [ 2020-03-18 ] Contributing Projects and Cores: Project 2 Structural Biology Core We performed an exhaustive crystallographic fragment screen to probe the Mpro active site, and to identify opportunities for fragment merging or growing. Additionally, a library of mild electrophilic fragments was screened by mass spectrometry for probing the binding properties around the active site cysteine. Overall, a total of 1742 soaking and 1139 co-crystallization experiments resulted in 1877 mounted crystals.</description></item><item><title>Publications</title><link>https://asapdiscovery.org/outputs/publications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/publications/</guid><description>ASAP aims to publish preprints to ensure our scientific advances are rapidly and openly available.</description></item><item><title>Analysis of Viral Mutations</title><link>https://asapdiscovery.org/outputs/circulating-variants/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/circulating-variants/</guid><description>Analysis of circulating variants of SARS-CoV-2 nsp5 Mpro protease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted. Analysis of circulating variants of SARS-CoV-2 nsp15 endoribonuclease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted.</description></item><item><title>Target Product Profiles (TPPs)</title><link>https://asapdiscovery.org/outputs/target-product-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-product-profiles/</guid><description>A Target Product Profile (TPP) describes the desired characteristics of a drug product aimed to treat a particular disease or set of diseases.
 All ASAP TPPs are draft TPPs intended to help guide the development of target candidate profiles (TCPs) for antiviral discovery within the ASAP Discovery Consortium. ASAP works with stakeholders around the globe (such as the World Health Organization) to align TPPs to ensure they meet the needs of communities and fulfill our mission of global, equitable, and affordable access to antiviral therapies.</description></item><item><title>Target Enabling Packages (TEPs)</title><link>https://asapdiscovery.org/outputs/target-enabling-packages/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-enabling-packages/</guid><description>A Target Enabling Package (TEP) is a complete data package needed to enable structure-based drug discovery against an antiviral target. Pioneered by the Structural Genomics Consortium, each TEP contains relevant protein constructs and plasmid resources for one or more viral family members, protein expression and purification protocols, crystallization conditions, structures from an X-ray fragment screen at the Diamond Light Source XChem facility, small molecule hits, and biochemical assay protocols with at least one validated inhibitor with quantifiable activity.</description></item><item><title>Assay Cascades</title><link>https://asapdiscovery.org/outputs/assay-cascades/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-cascades/</guid><description>An assay cascade is a defined set of assays and progression criteria used by a drug discovery program to achieve its Target Candidate Profile (TCP) goals in a time- and cost-effective manner.
 Assay cascade for MERS-CoV / SARS-CoV-2 oral antiviral [Asay Cascade (lead optimization)] Contributing Projects and Cores: Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2022-06-01] Initial draft DENV/ZIKV NS2B/3 3C protease [Assay Cascade] Assay cascade for DENV/ZIKV NS2B/3 3C Protease oral antiviral Contributing Projects and Cores: Project 3 Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2023-12-23] Initial draft EV-D68 / EV-A71 3C Protease Assay Cascade [Assay Cascade] Assay cascade for EV-D68 / EV-A71 3C Protease oral antiviral Contributing Projects and Cores: Project 3 Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2022-07-14] Initial draft Assay cascade for SARS-CoV-2 nsp3 Mac1 macrodomain oral antiviral [Assay Cascade (fragment-to-lead)] Partial SARS-CoV-2 nsp3 Mac1 macrodomain assay cascade for lead nomination Contributing Projects and Cores: Project 3 Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2022-06-01] Initial draft Assay cascade for SARS-CoV-2 Mpro oral antiviral [Assay Cascade (lead optimization)] Assay cascade for lead optimization campaign for SARS-CoV-2 noncovalent oral inhibitor from the COVID Moonshot [2020-03-23] Initial draft for COVID Moonshot</description></item><item><title>Assay Protocols</title><link>https://asapdiscovery.org/outputs/assay-protocols/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-protocols/</guid><description>ASAP frequently needs to develop or scale its own biochemical assay protocols to drive discovery programs. Whenever possible, we share these protocols through protocols.io, an industry standard platform for sharing and annotating assay protocols.
 MERS-CoV main protease (Mpro) activity fluorescence dose response biochemical assay [assay protocol] This is a functional, biochemical assay used to identify treatments for viral infectious disease in MERS 3C-like main viral protease. Utilizing a direct enzyme activity measurement method, the experiment was performed in a 384-well plate reading the fluorescence intensity.</description></item><item><title>Target Candidate Profiles (TCPs)</title><link>https://asapdiscovery.org/outputs/target-candidate-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-candidate-profiles/</guid><description>A Target Candidate Profile (TCP) describes the objectives an ASAP drug discovery program aims to achieve to produce a preclinical candidate. Our TCPs are informed by the corresponding Target Product Profiles (TPPs) for the corresponding disease.
diff --git a/outputs/circulating-variants/index.html b/outputs/circulating-variants/index.html
index 823953ef..9a527d03 100644
--- a/outputs/circulating-variants/index.html
+++ b/outputs/circulating-variants/index.html
@@ -1,8 +1,8 @@
-<!doctype html><html lang=en-us><head><meta name=generator content="Hugo 0.125.5"><meta charset=utf-8><meta http-equiv=X-UA-Compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><title>Analysis of Circulating Variants </title><meta name=description content="Analysis of circulating variants to identify potential resistance liabilities in functionally tolerated mutations"><meta name=author content="newpixcom"><meta property="og:url" content="https://asapdiscovery.org/outputs/circulating-variants/"><meta property="og:site_name" content="ASAP Discovery Consortium"><meta property="og:title" content="Analysis of Circulating Variants"><meta property="og:description" content="Analysis of circulating variants to identify potential resistance liabilities in functionally tolerated mutations"><meta property="og:locale" content="en-us"><meta property="og:type" content="article"><meta property="article:section" content="outputs"><div id=cookie-notice><span>We would like to use third party cookies and scripts to improve the
+<!doctype html><html lang=en-us><head><meta name=generator content="Hugo 0.125.5"><meta charset=utf-8><meta http-equiv=X-UA-Compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1"><title>Analysis of Viral Mutations </title><meta name=description content="Analysis of circulating and experimental variants to identify potential resistance liabilities in functionally tolerated mutations"><meta name=author content="newpixcom"><meta property="og:url" content="https://asapdiscovery.org/outputs/circulating-variants/"><meta property="og:site_name" content="ASAP Discovery Consortium"><meta property="og:title" content="Analysis of Viral Mutations"><meta property="og:description" content="Analysis of circulating and experimental variants to identify potential resistance liabilities in functionally tolerated mutations"><meta property="og:locale" content="en-us"><meta property="og:type" content="article"><meta property="article:section" content="outputs"><div id=cookie-notice><span>We would like to use third party cookies and scripts to improve the
 functionality of this website.</span>
 <a id=cookie-notice-accept class="btn btn-primary btn-sm">Approve</a>
 <a id=cookie-notice-deny class="btn btn-primary btn-sm">Deny</a>
-<a href=/privacy class="btn btn-primary btn-sm">More info</a></div><script>function createCookie(e,t,n){var s,o="";n&&(s=new Date,s.setTime(s.getTime()+n*24*60*60*1e3),o="; expires="+s.toUTCString()),document.cookie=e+"="+t+o+"; path=/"}function readCookie(e){for(var t,s=e+"=",o=document.cookie.split(";"),n=0;n<o.length;n++){for(t=o[n];t.charAt(0)==" ";)t=t.substring(1,t.length);if(t.indexOf(s)==0)return t.substring(s.length,t.length)}return null}function eraseCookie(e){createCookie(e,"",-1)}if(readCookie("cookie-notice-option")=="true"){function loadScriptAsync(e,t){if(typeof t!="function")throw new Error("Not a valid callback for async script load");var n=document.createElement("script");n.onload=t,n.src=e,document.head.appendChild(n)}loadScriptAsync("https://www.googletagmanager.com/gtag/js?id=G-M3L857X90H",function(){window.dataLayer=window.dataLayer||[];function e(){dataLayer.push(arguments)}e("js",new Date),e("config","G-M3L857X90H",{anonymize_ip:!0})})}else readCookie("cookie-notice-option")!="false"&&(document.getElementById("cookie-notice").style.display="block");document.getElementById("cookie-notice-accept").addEventListener("click",function(){createCookie("cookie-notice-option","true",31),document.getElementById("cookie-notice").style.display="none",location.reload()}),document.getElementById("cookie-notice-deny").addEventListener("click",function(){createCookie("cookie-notice-option","false",31),document.getElementById("cookie-notice").style.display="none",location.reload()})</script><link rel=canonical href=https://asapdiscovery.org/outputs/circulating-variants/><link rel="shortcut icon" type=image/png href="data:image/png;base64,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"><link href=/css/font.css rel=stylesheet type=text/css><link href=/css/kube.css rel=stylesheet type=text/css><link href=/css/kube.legenda.css rel=stylesheet type=text/css><link href=/css/highlight.css rel=stylesheet type=text/css><link href=/css/master.css rel=stylesheet type=text/css><link href=/css/kube.demo.css rel=stylesheet type=text/css><link href=/css/custom.css rel=stylesheet type=text/css><script src=/js/jquery-2.1.4.min.js type=text/javascript></script><script type=text/javascript src=/js/tocbot.min.js></script></head><body class=page-kube><header><div class=show-sm><div id=nav-toggle-box><div id=nav-toggle-brand><a href=/>ASAP Discovery Consortium</a></div><a data-component=toggleme data-target=#top href=# id=nav-toggle><i class=kube-menu></i></a></div></div><div class=hide-sm id=top><div id=top-brand><a href=/ title=home>ASAP Discovery Consortium</a></div><nav id=top-nav-main><ul><li><a href=/pipeline/>Pipeline</a></li><li><a href=/outputs/>Outputs</a></li><li><a href=https://www.choderalab.org/news/2021/10/26/asap-avidd-proposal>Concept</a></li><li><a href=/members/>Members</a></li><li><a href=/sab/>SAB</a></li><li><a href=/faq/>FAQ</a></li><li><a href=/awards/>Awards</a></li><li><a href=/forum/>Open Science Forum</a></li><li><a href=https://postera.ai/moonshot/>COVID Moonshot</a></li></ul></nav><nav id=top-nav-extra><ul></ul></nav></div></header><main><div id=main><div id=hero><h1>Analysis of Circulating Variants</h1><p class=hero-lead></p><div class="message error" data-component=message>This page is still in development. Please report any issues to <a href=https://github.com/asapdiscovery/asapdiscovery.github.io/issues>our issue tracker</a>.</div></div><div id=kube-component class=content><nav id=contents><ol class=js-toc></ol></nav><script type=text/javascript>document.addEventListener("DOMContentLoaded",function(){tocbot.init({tocSelector:".js-toc",contentSelector:".content",headingSelector:"h3"})})</script><div class=prettybox data-component=prettybox><h3 style=text-align:left id=ASAP-COV-MPRO>Analysis of circulating variants of SARS-CoV-2 nsp5 Mpro protease</h3><a href=https://jbloomlab.github.io/SARS2-mut-fitness/nsp5.html>[interactive viewer]</a>
+<a href=/privacy class="btn btn-primary btn-sm">More info</a></div><script>function createCookie(e,t,n){var s,o="";n&&(s=new Date,s.setTime(s.getTime()+n*24*60*60*1e3),o="; expires="+s.toUTCString()),document.cookie=e+"="+t+o+"; path=/"}function readCookie(e){for(var t,s=e+"=",o=document.cookie.split(";"),n=0;n<o.length;n++){for(t=o[n];t.charAt(0)==" ";)t=t.substring(1,t.length);if(t.indexOf(s)==0)return t.substring(s.length,t.length)}return null}function eraseCookie(e){createCookie(e,"",-1)}if(readCookie("cookie-notice-option")=="true"){function loadScriptAsync(e,t){if(typeof t!="function")throw new Error("Not a valid callback for async script load");var n=document.createElement("script");n.onload=t,n.src=e,document.head.appendChild(n)}loadScriptAsync("https://www.googletagmanager.com/gtag/js?id=G-M3L857X90H",function(){window.dataLayer=window.dataLayer||[];function e(){dataLayer.push(arguments)}e("js",new Date),e("config","G-M3L857X90H",{anonymize_ip:!0})})}else readCookie("cookie-notice-option")!="false"&&(document.getElementById("cookie-notice").style.display="block");document.getElementById("cookie-notice-accept").addEventListener("click",function(){createCookie("cookie-notice-option","true",31),document.getElementById("cookie-notice").style.display="none",location.reload()}),document.getElementById("cookie-notice-deny").addEventListener("click",function(){createCookie("cookie-notice-option","false",31),document.getElementById("cookie-notice").style.display="none",location.reload()})</script><link rel=canonical href=https://asapdiscovery.org/outputs/circulating-variants/><link rel="shortcut icon" type=image/png href="data:image/png;base64,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"><link href=/css/font.css rel=stylesheet type=text/css><link href=/css/kube.css rel=stylesheet type=text/css><link href=/css/kube.legenda.css rel=stylesheet type=text/css><link href=/css/highlight.css rel=stylesheet type=text/css><link href=/css/master.css rel=stylesheet type=text/css><link href=/css/kube.demo.css rel=stylesheet type=text/css><link href=/css/custom.css rel=stylesheet type=text/css><script src=/js/jquery-2.1.4.min.js type=text/javascript></script><script type=text/javascript src=/js/tocbot.min.js></script></head><body class=page-kube><header><div class=show-sm><div id=nav-toggle-box><div id=nav-toggle-brand><a href=/>ASAP Discovery Consortium</a></div><a data-component=toggleme data-target=#top href=# id=nav-toggle><i class=kube-menu></i></a></div></div><div class=hide-sm id=top><div id=top-brand><a href=/ title=home>ASAP Discovery Consortium</a></div><nav id=top-nav-main><ul><li><a href=/pipeline/>Pipeline</a></li><li><a href=/outputs/>Outputs</a></li><li><a href=https://www.choderalab.org/news/2021/10/26/asap-avidd-proposal>Concept</a></li><li><a href=/members/>Members</a></li><li><a href=/sab/>SAB</a></li><li><a href=/faq/>FAQ</a></li><li><a href=/awards/>Awards</a></li><li><a href=/forum/>Open Science Forum</a></li><li><a href=https://postera.ai/moonshot/>COVID Moonshot</a></li></ul></nav><nav id=top-nav-extra><ul></ul></nav></div></header><main><div id=main><div id=hero><h1>Analysis of Viral Mutations</h1><p class=hero-lead></p><div class="message error" data-component=message>This page is still in development. Please report any issues to <a href=https://github.com/asapdiscovery/asapdiscovery.github.io/issues>our issue tracker</a>.</div></div><div id=kube-component class=content><nav id=contents><ol class=js-toc></ol></nav><script type=text/javascript>document.addEventListener("DOMContentLoaded",function(){tocbot.init({tocSelector:".js-toc",contentSelector:".content",headingSelector:"h3"})})</script><div class=prettybox data-component=prettybox><h3 style=text-align:left id=ASAP-COV-MPRO>Analysis of circulating variants of SARS-CoV-2 nsp5 Mpro protease</h3><a href=https://jbloomlab.github.io/SARS2-mut-fitness/nsp5.html>[interactive viewer]</a>
 <a href=https://doi.org/10.1101/2023.01.30.526314>[bioRxiv preprint]</a><br>Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants<br>Contributing Projects and Cores:
 <span class="label focus">Project 1</span><br><small><i>[2023-01-31]</i> Preprint and interactive mutation viewer posted.</small><br></div><div class=prettybox data-component=prettybox><h3 style=text-align:left id=ASAP-SARS-COV-2-ENDORIBONUCLEASE>Analysis of circulating variants of SARS-CoV-2 nsp15 endoribonuclease</h3><a href=https://jbloomlab.github.io/SARS2-mut-fitness/nsp15.html>[interactive viewer]</a>
 <a href=https://doi.org/10.1101/2023.01.30.526314>[bioRxiv preprint]</a><br>Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants<br>Contributing Projects and Cores:
@@ -12,7 +12,9 @@
 <a href=https://doi.org/10.1101/2023.01.30.526314>[bioRxiv preprint]</a><br>Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants<br>Contributing Projects and Cores:
 <span class="label focus">Project 1</span><br><small><i>[2023-01-31]</i> Preprint and interactive mutation viewer posted.</small><br></div><div class=prettybox data-component=prettybox><h3 style=text-align:left id=ASAP-SARS-COV-2-NSP3-MAC1>Analysis of circulating variants of SARS-CoV-2 nsp3 Mac1 macrodomain</h3><a href=https://jbloomlab.github.io/SARS2-mut-fitness/nsp3.html>[interactive viewer]</a>
 <a href=https://doi.org/10.1101/2023.01.30.526314>[bioRxiv preprint]</a><br>Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants<br>Contributing Projects and Cores:
-<span class="label focus">Project 1</span><br><small><i>[2023-01-31]</i> Preprint and interactive mutation viewer posted.</small><br></div><div class=prettybox data-component=prettybox><h3 style=text-align:left id=MOONSHOT-COV-MPRO>Analysis of circulating variants of SARS-CoV-2 nsp5 Mpro protease</h3><a href=https://jbloomlab.github.io/SARS2-mut-fitness/nsp5.html>[interactive viewer]</a>
+<span class="label focus">Project 1</span><br><small><i>[2023-01-31]</i> Preprint and interactive mutation viewer posted.</small><br></div><div class=prettybox data-component=prettybox><h3 style=text-align:left id=ASAP-ZIKV-NS2B3>Analysis of mutational space with Deep Mutational Scanning of ZIKV NS2B/3 protease</h3><a href=https://github.com/jbloomlab/ZIKV_DMS_NS3_EvansLab/tree/master>[dataset download]</a><br>Dataset download of fitness data gathered by Deep Mutational Scanning performed by Evans lab, analyzed by Bloom lab<br>Contributing Projects and Cores:
+<span class="label focus">Project 1</span><br><small><i>[2023-11-01]</i> Initial version of analyzed data posted.</small><br></div><div class=prettybox data-component=prettybox><h3 style=text-align:left id=ASAP-ZIKV-RdRp-polymerase>Analysis of mutational space with Deep Mutational Scanning of ZIKV RdRp polymerase (NS5)</h3><a href=https://github.com/jbloomlab/ZIKV_DMS_NS5_EvansLab/tree/IFN_signaling>[dataset download]</a><br>Dataset download of fitness data gathered by Deep Mutational Scanning performed by Evans lab, analyzed by Bloom lab<br>Contributing Projects and Cores:
+<span class="label focus">Project 1</span><br><small><i>[2024-04-01]</i> Initial version of analyzed data posted.</small><br></div><div class=prettybox data-component=prettybox><h3 style=text-align:left id=MOONSHOT-COV-MPRO>Analysis of circulating variants of SARS-CoV-2 nsp5 Mpro protease</h3><a href=https://jbloomlab.github.io/SARS2-mut-fitness/nsp5.html>[interactive viewer]</a>
 <a href=https://doi.org/10.1101/2023.01.30.526314>[bioRxiv preprint]</a><br>Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants<br><small><i>[2023-01-31]</i> Preprint and interactive mutation viewer posted.</small><br></div><div class=prettybox data-component=prettybox><h3 style=text-align:left id=NONE-SARS-COV-2-NSP1>Analysis of circulating variants of SARS-CoV-2 nsp1</h3><a href=https://jbloomlab.github.io/SARS2-mut-fitness/nsp1.html>[interactive viewer]</a>
 <a href=https://doi.org/10.1101/2023.01.30.526314>[bioRxiv preprint]</a><br>Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants<br>Contributing Projects and Cores:
 <span class="label focus">Project 1</span><br><small><i>[2023-01-31]</i> Preprint and interactive mutation viewer posted.</small><br></div><div class=prettybox data-component=prettybox><h3 style=text-align:left id=NONE-SARS-COV-2-NSP12>Analysis of circulating variants of SARS-CoV-2 nsp12 RdRp</h3><a href=https://jbloomlab.github.io/SARS2-mut-fitness/nsp12.html>[interactive viewer]</a>
diff --git a/outputs/index.html b/outputs/index.html
index 6a9e0aa0..57d3739c 100644
--- a/outputs/index.html
+++ b/outputs/index.html
@@ -2,4 +2,4 @@
 functionality of this website.</span>
 <a id=cookie-notice-accept class="btn btn-primary btn-sm">Approve</a>
 <a id=cookie-notice-deny class="btn btn-primary btn-sm">Deny</a>
-<a href=/privacy class="btn btn-primary btn-sm">More info</a></div><script>function createCookie(e,t,n){var s,o="";n&&(s=new Date,s.setTime(s.getTime()+n*24*60*60*1e3),o="; expires="+s.toUTCString()),document.cookie=e+"="+t+o+"; path=/"}function readCookie(e){for(var t,s=e+"=",o=document.cookie.split(";"),n=0;n<o.length;n++){for(t=o[n];t.charAt(0)==" ";)t=t.substring(1,t.length);if(t.indexOf(s)==0)return t.substring(s.length,t.length)}return null}function eraseCookie(e){createCookie(e,"",-1)}if(readCookie("cookie-notice-option")=="true"){function loadScriptAsync(e,t){if(typeof t!="function")throw new Error("Not a valid callback for async script load");var n=document.createElement("script");n.onload=t,n.src=e,document.head.appendChild(n)}loadScriptAsync("https://www.googletagmanager.com/gtag/js?id=G-M3L857X90H",function(){window.dataLayer=window.dataLayer||[];function e(){dataLayer.push(arguments)}e("js",new Date),e("config","G-M3L857X90H",{anonymize_ip:!0})})}else readCookie("cookie-notice-option")!="false"&&(document.getElementById("cookie-notice").style.display="block");document.getElementById("cookie-notice-accept").addEventListener("click",function(){createCookie("cookie-notice-option","true",31),document.getElementById("cookie-notice").style.display="none",location.reload()}),document.getElementById("cookie-notice-deny").addEventListener("click",function(){createCookie("cookie-notice-option","false",31),document.getElementById("cookie-notice").style.display="none",location.reload()})</script><link rel=canonical href=https://asapdiscovery.org/outputs/><link rel="shortcut icon" type=image/png href="data:image/png;base64,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"><link href=/css/font.css rel=stylesheet type=text/css><link href=/css/kube.css rel=stylesheet type=text/css><link href=/css/kube.legenda.css rel=stylesheet type=text/css><link href=/css/highlight.css rel=stylesheet type=text/css><link href=/css/master.css rel=stylesheet type=text/css><link href=/css/kube.demo.css rel=stylesheet type=text/css><link href=/css/custom.css rel=stylesheet type=text/css><script src=/js/jquery-2.1.4.min.js type=text/javascript></script><script type=text/javascript src=/js/tocbot.min.js></script></head><body class=page-kube><header><div class=show-sm><div id=nav-toggle-box><div id=nav-toggle-brand><a href=/>ASAP Discovery Consortium</a></div><a data-component=toggleme data-target=#top href=# id=nav-toggle><i class=kube-menu></i></a></div></div><div class=hide-sm id=top><div id=top-brand><a href=/ title=home>ASAP Discovery Consortium</a></div><nav id=top-nav-main><ul><li><a href=/pipeline/>Pipeline</a></li><li><a href=/outputs/>Outputs</a></li><li><a href=https://www.choderalab.org/news/2021/10/26/asap-avidd-proposal>Concept</a></li><li><a href=/members/>Members</a></li><li><a href=/sab/>SAB</a></li><li><a href=/faq/>FAQ</a></li><li><a href=/awards/>Awards</a></li><li><a href=/forum/>Open Science Forum</a></li><li><a href=https://postera.ai/moonshot/>COVID Moonshot</a></li></ul></nav><nav id=top-nav-extra><ul></ul></nav></div></header><main><div id=main><div id=hero><h1>ASAP Discovery Outputs</h1></div><div id=components><div class="row gutters"><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/viral-families/>Viral Families</a></h4><p>Viral families targeted by ASAP</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/software/>Software</a></h4><p>Software produced by ASAP</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/targeting-opportunities/>Targeting Opportunities</a></h4><p>ASAP identified discovery opportunities for broad antiviral activity</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/molecules/>Molecules</a></h4><p>Assayed compounds and biochemical data</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/structures/>Structures</a></h4><p>Structures of ASAP targets with inhibitors</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/publications/>Publications</a></h4><p>Scientific publications from ASAP</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/circulating-variants/>Analysis of Circulating Variants</a></h4><p>Analysis of circulating variants to identify potential resistance liabilities in functionally tolerated mutations</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/target-product-profiles/>Target Product Profiles (TPPs)</a></h4><p>Target Product Profiles (TPPs) guiding ASAP discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/target-enabling-packages/>Target Enabling Packages (TEPs)</a></h4><p>ASAP Target Enabling Packages (TEPs) for initiating structure-based drug discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/assay-cascades/>Assay Cascades</a></h4><p>Assay cascades used by ASAP Discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/assay-protocols/>Assay Protocols</a></h4><p>Assay protocols developed for ASAP Discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/target-candidate-profiles/>Target Candidate Profiles (TCPs)</a></h4><p>Target Candidate Profiles (TCPs) guiding ASAP discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/preclinical/>Preclinical programs</a></h4><p>Preclinical data packages</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/investigational-new-drugs/>Investigational New Drug (IND) filings</a></h4><p>IND (and IND-equivalent) filing packages for ASAP preclinical programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/clinical-trials/>Clinical trials</a></h4><p>ASAP clinical trials</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/new-drug-approvals/>New Drug Approvals</a></h4><p>ASAP New Drug Approvals (NDAs)</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/img/icons/readme/></a></h4><p></p></div></div></div></div></main><footer><footer id=footer><nav><ul><li><span>ASAP Discovery</span></li><li><a href=/concept>About Us</a></li><li><a href=/credits>Image Credits</a></li><li><a href=mailto:maggie.jameson@choderalab.org>Contact Us</a></li></ul></nav></footer><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.7.1/katex.min.css integrity=sha384-wITovz90syo1dJWVh32uuETPVEtGigN07tkttEqPv+uR2SE/mbQcG7ATL28aI9H0 crossorigin=anonymous><script src=https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.7.1/katex.min.js integrity=sha384-/y1Nn9+QQAipbNQWU65krzJralCnuOasHncUFXGkdwntGeSvQicrYkiUBwsgUqc1 crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.7.1/contrib/auto-render.min.js integrity=sha384-dq1/gEHSxPZQ7DdrM82ID4YVol9BYyU7GbWlIwnwyPzotpoc57wDw/guX8EaYGPx crossorigin=anonymous></script><script>renderMathInElement(document.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}]});for(var inlineMath,tex,replaced,displayMathArray,displayMath,inlineMathArray=document.querySelectorAll("script[type='math/tex']"),i=0;i<inlineMathArray.length;i++)inlineMath=inlineMathArray[i],tex=inlineMath.innerText||inlineMath.textContent,replaced=document.createElement("span"),replaced.innerHTML=katex.renderToString(tex,{displayMode:!1}),inlineMath.parentNode.replaceChild(replaced,inlineMath);for(displayMathArray=document.querySelectorAll("script[type='math/tex; mode=display']"),i=0;i<displayMathArray.length;i++)displayMath=displayMathArray[i],tex=displayMath.innerHTML,replaced=document.createElement("span"),replaced.innerHTML=katex.renderToString(tex.replace(/%.*/g,""),{displayMode:!0}),displayMath.parentNode.replaceChild(replaced,displayMath)</script><script>renderMathInElement(document.body)</script></footer><script src=/js/kube.js type=text/javascript></script><script src=/js/kube.legenda.js type=text/javascript></script><script src=/js/master.js type=text/javascript></script></body></html>
\ No newline at end of file
+<a href=/privacy class="btn btn-primary btn-sm">More info</a></div><script>function createCookie(e,t,n){var s,o="";n&&(s=new Date,s.setTime(s.getTime()+n*24*60*60*1e3),o="; expires="+s.toUTCString()),document.cookie=e+"="+t+o+"; path=/"}function readCookie(e){for(var t,s=e+"=",o=document.cookie.split(";"),n=0;n<o.length;n++){for(t=o[n];t.charAt(0)==" ";)t=t.substring(1,t.length);if(t.indexOf(s)==0)return t.substring(s.length,t.length)}return null}function eraseCookie(e){createCookie(e,"",-1)}if(readCookie("cookie-notice-option")=="true"){function loadScriptAsync(e,t){if(typeof t!="function")throw new Error("Not a valid callback for async script load");var n=document.createElement("script");n.onload=t,n.src=e,document.head.appendChild(n)}loadScriptAsync("https://www.googletagmanager.com/gtag/js?id=G-M3L857X90H",function(){window.dataLayer=window.dataLayer||[];function e(){dataLayer.push(arguments)}e("js",new Date),e("config","G-M3L857X90H",{anonymize_ip:!0})})}else readCookie("cookie-notice-option")!="false"&&(document.getElementById("cookie-notice").style.display="block");document.getElementById("cookie-notice-accept").addEventListener("click",function(){createCookie("cookie-notice-option","true",31),document.getElementById("cookie-notice").style.display="none",location.reload()}),document.getElementById("cookie-notice-deny").addEventListener("click",function(){createCookie("cookie-notice-option","false",31),document.getElementById("cookie-notice").style.display="none",location.reload()})</script><link rel=canonical href=https://asapdiscovery.org/outputs/><link rel="shortcut icon" type=image/png href="data:image/png;base64,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"><link href=/css/font.css rel=stylesheet type=text/css><link href=/css/kube.css rel=stylesheet type=text/css><link href=/css/kube.legenda.css rel=stylesheet type=text/css><link href=/css/highlight.css rel=stylesheet type=text/css><link href=/css/master.css rel=stylesheet type=text/css><link href=/css/kube.demo.css rel=stylesheet type=text/css><link href=/css/custom.css rel=stylesheet type=text/css><script src=/js/jquery-2.1.4.min.js type=text/javascript></script><script type=text/javascript src=/js/tocbot.min.js></script></head><body class=page-kube><header><div class=show-sm><div id=nav-toggle-box><div id=nav-toggle-brand><a href=/>ASAP Discovery Consortium</a></div><a data-component=toggleme data-target=#top href=# id=nav-toggle><i class=kube-menu></i></a></div></div><div class=hide-sm id=top><div id=top-brand><a href=/ title=home>ASAP Discovery Consortium</a></div><nav id=top-nav-main><ul><li><a href=/pipeline/>Pipeline</a></li><li><a href=/outputs/>Outputs</a></li><li><a href=https://www.choderalab.org/news/2021/10/26/asap-avidd-proposal>Concept</a></li><li><a href=/members/>Members</a></li><li><a href=/sab/>SAB</a></li><li><a href=/faq/>FAQ</a></li><li><a href=/awards/>Awards</a></li><li><a href=/forum/>Open Science Forum</a></li><li><a href=https://postera.ai/moonshot/>COVID Moonshot</a></li></ul></nav><nav id=top-nav-extra><ul></ul></nav></div></header><main><div id=main><div id=hero><h1>ASAP Discovery Outputs</h1></div><div id=components><div class="row gutters"><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/viral-families/>Viral Families</a></h4><p>Viral families targeted by ASAP</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/software/>Software</a></h4><p>Software produced by ASAP</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/targeting-opportunities/>Targeting Opportunities</a></h4><p>ASAP identified discovery opportunities for broad antiviral activity</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/molecules/>Molecules</a></h4><p>Assayed compounds and biochemical data</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/structures/>Structures</a></h4><p>Structures of ASAP targets with inhibitors</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/publications/>Publications</a></h4><p>Scientific publications from ASAP</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/circulating-variants/>Analysis of Viral Mutations</a></h4><p>Analysis of circulating and experimental variants to identify potential resistance liabilities in functionally tolerated mutations</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/target-product-profiles/>Target Product Profiles (TPPs)</a></h4><p>Target Product Profiles (TPPs) guiding ASAP discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/target-enabling-packages/>Target Enabling Packages (TEPs)</a></h4><p>ASAP Target Enabling Packages (TEPs) for initiating structure-based drug discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/assay-cascades/>Assay Cascades</a></h4><p>Assay cascades used by ASAP Discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/assay-protocols/>Assay Protocols</a></h4><p>Assay protocols developed for ASAP Discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/target-candidate-profiles/>Target Candidate Profiles (TCPs)</a></h4><p>Target Candidate Profiles (TCPs) guiding ASAP discovery programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/preclinical/>Preclinical programs</a></h4><p>Preclinical data packages</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/investigational-new-drugs/>Investigational New Drug (IND) filings</a></h4><p>IND (and IND-equivalent) filing packages for ASAP preclinical programs</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/clinical-trials/>Clinical trials</a></h4><p>ASAP clinical trials</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/new-drug-approvals/>New Drug Approvals</a></h4><p>ASAP New Drug Approvals (NDAs)</p></div><div class="col col-4 item"><h4><a href=https://asapdiscovery.org/outputs/img/icons/readme/></a></h4><p></p></div></div></div></div></main><footer><footer id=footer><nav><ul><li><span>ASAP Discovery</span></li><li><a href=/concept>About Us</a></li><li><a href=/credits>Image Credits</a></li><li><a href=mailto:maggie.jameson@choderalab.org>Contact Us</a></li></ul></nav></footer><link rel=stylesheet href=https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.7.1/katex.min.css integrity=sha384-wITovz90syo1dJWVh32uuETPVEtGigN07tkttEqPv+uR2SE/mbQcG7ATL28aI9H0 crossorigin=anonymous><script src=https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.7.1/katex.min.js integrity=sha384-/y1Nn9+QQAipbNQWU65krzJralCnuOasHncUFXGkdwntGeSvQicrYkiUBwsgUqc1 crossorigin=anonymous></script><script src=https://cdnjs.cloudflare.com/ajax/libs/KaTeX/0.7.1/contrib/auto-render.min.js integrity=sha384-dq1/gEHSxPZQ7DdrM82ID4YVol9BYyU7GbWlIwnwyPzotpoc57wDw/guX8EaYGPx crossorigin=anonymous></script><script>renderMathInElement(document.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}]});for(var inlineMath,tex,replaced,displayMathArray,displayMath,inlineMathArray=document.querySelectorAll("script[type='math/tex']"),i=0;i<inlineMathArray.length;i++)inlineMath=inlineMathArray[i],tex=inlineMath.innerText||inlineMath.textContent,replaced=document.createElement("span"),replaced.innerHTML=katex.renderToString(tex,{displayMode:!1}),inlineMath.parentNode.replaceChild(replaced,inlineMath);for(displayMathArray=document.querySelectorAll("script[type='math/tex; mode=display']"),i=0;i<displayMathArray.length;i++)displayMath=displayMathArray[i],tex=displayMath.innerHTML,replaced=document.createElement("span"),replaced.innerHTML=katex.renderToString(tex.replace(/%.*/g,""),{displayMode:!0}),displayMath.parentNode.replaceChild(replaced,displayMath)</script><script>renderMathInElement(document.body)</script></footer><script src=/js/kube.js type=text/javascript></script><script src=/js/kube.legenda.js type=text/javascript></script><script src=/js/master.js type=text/javascript></script></body></html>
\ No newline at end of file
diff --git a/outputs/index.xml b/outputs/index.xml
index 1b117f32..906da6c7 100644
--- a/outputs/index.xml
+++ b/outputs/index.xml
@@ -2,7 +2,7 @@
 coronaviridae Coronavirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.
 flaviviridae Flavivirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.</description></item><item><title>Software</title><link>https://asapdiscovery.org/outputs/software/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/software/</guid><description>Software produced by ASAP.
 argos [GitHub] A web-based visualization tool for viewing DMS data on protein structures that allows users to generate and share these views using a web UI. See &amp;lsquo;choppa&amp;rsquo; package below. Contributing Projects and Cores: Project 2 Computational Chemistry Core asapdiscovery [GitHub] [Documentation] Monorepository for running computational chemistry project support for ASAP&amp;rsquo;s viral targets, including docking, free energy calculations, chemoinformatics and machine learning. Contributing Projects and Cores: Project 5 Computational Chemistry Core choppa [GitHub] [Documentation] A Python library for visualizing Deep Mutational Scanning data and other fitness data directly onto protein structures to enable fitness-informed decision-making in medicinal chemistry workflows in P2-P5 of ASAP&amp;rsquo;s drug discovery pipeline.</description></item><item><title>Targeting Opportunities</title><link>https://asapdiscovery.org/outputs/targeting-opportunities/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/targeting-opportunities/</guid><description>A targeting opportunity provides an overview of the opportunity for targeting new antivirals to a specific target protein and mode of action. This overview is intended to summarize relevant information for drug hunters, including the relevant domain and binding sites to target, notable chemical matter, rationale for antiviral effects, and other useful information in prosecuting a discovery compaign aginst the target.
-Targeting Opportunity: SARS-CoV-2 / MERS-CoV Mpro protease [Targeting Opportunity] Contributing Projects and Cores: Project 1 Project 5 [2023-03-19] Initial draft [2024-04-29] Major update of the targeting opportunity covering clinical background, history of outbreaks, viral biology, target biochemistry, phylogenetic analysis, etc.</description></item><item><title>Molecules</title><link>https://asapdiscovery.org/outputs/molecules/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/molecules/</guid><description>SARS-CoV-2/MERS-CoV Mpro lead optimization assay data [metadata] [(negative) biochemical and liver microsome assay data [Oct 2023]] [(negative) biochemical and liver microsome assay data [Mar 2024]] [SARS-CoV-2 Mpro assay protocol] [MERS-CoV Mpro assay protocol] This data release contains assay data for compounds ASAP is not pursuing toward nomination of a development candidate as part of this discovery program. Contributing Projects and Cores: Project 5 Biochemical Assay Core Data Core [2023-04-30] Initial public release of negative biochemical activity data for 182 molecules.</description></item><item><title>Structures</title><link>https://asapdiscovery.org/outputs/structures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/structures/</guid><description>MERS-CoV/SARS-CoV-2 Mpro protease ASAP-COV-MPRO XChem crystallographic fragment screen of SARS-CoV-2 Mpro xray-fragment-screen [ 2020-03-18 ] Contributing Projects and Cores: Project 2 Structural Biology Core We performed an exhaustive crystallographic fragment screen to probe the Mpro active site, and to identify opportunities for fragment merging or growing. Additionally, a library of mild electrophilic fragments was screened by mass spectrometry for probing the binding properties around the active site cysteine. Overall, a total of 1742 soaking and 1139 co-crystallization experiments resulted in 1877 mounted crystals.</description></item><item><title>Publications</title><link>https://asapdiscovery.org/outputs/publications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/publications/</guid><description>ASAP aims to publish preprints to ensure our scientific advances are rapidly and openly available.</description></item><item><title>Analysis of Circulating Variants</title><link>https://asapdiscovery.org/outputs/circulating-variants/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/circulating-variants/</guid><description>Analysis of circulating variants of SARS-CoV-2 nsp5 Mpro protease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted. Analysis of circulating variants of SARS-CoV-2 nsp15 endoribonuclease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted.</description></item><item><title>Target Product Profiles (TPPs)</title><link>https://asapdiscovery.org/outputs/target-product-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-product-profiles/</guid><description>A Target Product Profile (TPP) describes the desired characteristics of a drug product aimed to treat a particular disease or set of diseases.
+Targeting Opportunity: SARS-CoV-2 / MERS-CoV Mpro protease [Targeting Opportunity] Contributing Projects and Cores: Project 1 Project 5 [2023-03-19] Initial draft [2024-04-29] Major update of the targeting opportunity covering clinical background, history of outbreaks, viral biology, target biochemistry, phylogenetic analysis, etc.</description></item><item><title>Molecules</title><link>https://asapdiscovery.org/outputs/molecules/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/molecules/</guid><description>SARS-CoV-2/MERS-CoV Mpro lead optimization assay data [metadata] [(negative) biochemical and liver microsome assay data [Oct 2023]] [(negative) biochemical and liver microsome assay data [Mar 2024]] [SARS-CoV-2 Mpro assay protocol] [MERS-CoV Mpro assay protocol] This data release contains assay data for compounds ASAP is not pursuing toward nomination of a development candidate as part of this discovery program. Contributing Projects and Cores: Project 5 Biochemical Assay Core Data Core [2023-04-30] Initial public release of negative biochemical activity data for 182 molecules.</description></item><item><title>Structures</title><link>https://asapdiscovery.org/outputs/structures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/structures/</guid><description>MERS-CoV/SARS-CoV-2 Mpro protease ASAP-COV-MPRO XChem crystallographic fragment screen of SARS-CoV-2 Mpro xray-fragment-screen [ 2020-03-18 ] Contributing Projects and Cores: Project 2 Structural Biology Core We performed an exhaustive crystallographic fragment screen to probe the Mpro active site, and to identify opportunities for fragment merging or growing. Additionally, a library of mild electrophilic fragments was screened by mass spectrometry for probing the binding properties around the active site cysteine. Overall, a total of 1742 soaking and 1139 co-crystallization experiments resulted in 1877 mounted crystals.</description></item><item><title>Publications</title><link>https://asapdiscovery.org/outputs/publications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/publications/</guid><description>ASAP aims to publish preprints to ensure our scientific advances are rapidly and openly available.</description></item><item><title>Analysis of Viral Mutations</title><link>https://asapdiscovery.org/outputs/circulating-variants/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/circulating-variants/</guid><description>Analysis of circulating variants of SARS-CoV-2 nsp5 Mpro protease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted. Analysis of circulating variants of SARS-CoV-2 nsp15 endoribonuclease [interactive viewer] [bioRxiv preprint] Interactive viewer and dataset download of functional mutation impact scores derived from analysis of circulating SARS-CoV-2 variants Contributing Projects and Cores: Project 1 [2023-01-31] Preprint and interactive mutation viewer posted.</description></item><item><title>Target Product Profiles (TPPs)</title><link>https://asapdiscovery.org/outputs/target-product-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-product-profiles/</guid><description>A Target Product Profile (TPP) describes the desired characteristics of a drug product aimed to treat a particular disease or set of diseases.
 All ASAP TPPs are draft TPPs intended to help guide the development of target candidate profiles (TCPs) for antiviral discovery within the ASAP Discovery Consortium. ASAP works with stakeholders around the globe (such as the World Health Organization) to align TPPs to ensure they meet the needs of communities and fulfill our mission of global, equitable, and affordable access to antiviral therapies.</description></item><item><title>Target Enabling Packages (TEPs)</title><link>https://asapdiscovery.org/outputs/target-enabling-packages/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-enabling-packages/</guid><description>A Target Enabling Package (TEP) is a complete data package needed to enable structure-based drug discovery against an antiviral target. Pioneered by the Structural Genomics Consortium, each TEP contains relevant protein constructs and plasmid resources for one or more viral family members, protein expression and purification protocols, crystallization conditions, structures from an X-ray fragment screen at the Diamond Light Source XChem facility, small molecule hits, and biochemical assay protocols with at least one validated inhibitor with quantifiable activity.</description></item><item><title>Assay Cascades</title><link>https://asapdiscovery.org/outputs/assay-cascades/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-cascades/</guid><description>An assay cascade is a defined set of assays and progression criteria used by a drug discovery program to achieve its Target Candidate Profile (TCP) goals in a time- and cost-effective manner.
 Assay cascade for MERS-CoV / SARS-CoV-2 oral antiviral [Asay Cascade (lead optimization)] Contributing Projects and Cores: Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2022-06-01] Initial draft DENV/ZIKV NS2B/3 3C protease [Assay Cascade] Assay cascade for DENV/ZIKV NS2B/3 3C Protease oral antiviral Contributing Projects and Cores: Project 3 Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2023-12-23] Initial draft EV-D68 / EV-A71 3C Protease Assay Cascade [Assay Cascade] Assay cascade for EV-D68 / EV-A71 3C Protease oral antiviral Contributing Projects and Cores: Project 3 Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2022-07-14] Initial draft Assay cascade for SARS-CoV-2 nsp3 Mac1 macrodomain oral antiviral [Assay Cascade (fragment-to-lead)] Partial SARS-CoV-2 nsp3 Mac1 macrodomain assay cascade for lead nomination Contributing Projects and Cores: Project 3 Project 5 Biochemical Assay Core Structural Biology Core Antiviral Core [2022-06-01] Initial draft Assay cascade for SARS-CoV-2 Mpro oral antiviral [Assay Cascade (lead optimization)] Assay cascade for lead optimization campaign for SARS-CoV-2 noncovalent oral inhibitor from the COVID Moonshot [2020-03-23] Initial draft for COVID Moonshot</description></item><item><title>Assay Protocols</title><link>https://asapdiscovery.org/outputs/assay-protocols/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-protocols/</guid><description>ASAP frequently needs to develop or scale its own biochemical assay protocols to drive discovery programs. Whenever possible, we share these protocols through protocols.io, an industry standard platform for sharing and annotating assay protocols.
 MERS-CoV main protease (Mpro) activity fluorescence dose response biochemical assay [assay protocol] This is a functional, biochemical assay used to identify treatments for viral infectious disease in MERS 3C-like main viral protease. Utilizing a direct enzyme activity measurement method, the experiment was performed in a 384-well plate reading the fluorescence intensity.</description></item><item><title>Target Candidate Profiles (TCPs)</title><link>https://asapdiscovery.org/outputs/target-candidate-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-candidate-profiles/</guid><description>A Target Candidate Profile (TCP) describes the objectives an ASAP drug discovery program aims to achieve to produce a preclinical candidate. Our TCPs are informed by the corresponding Target Product Profiles (TPPs) for the corresponding disease.